Rhythm Pharmaceuticals, Inc. (RYTM) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Boston, MA, United States. वर्तमान CEO हैं David Meeker.
RYTM के पास है IPO तिथि 2017-10-09, 283 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $5.96B.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of therapeutics for rare genetic diseases of obesity. The company's lead product, IMCIVREE, is a melanocortin-4 receptor agonist approved for treating obesity caused by POMC, PCSK1, and LEPR deficiencies, as well as Bardet-Biedl and Alström syndromes. Rhythm is also advancing setmelanotide through Phase II clinical trials for multiple rare genetic obesity indications, including heterozygous POMC or LEPR deficiency, SH2B1 deficiency, MC4 receptor deficiency, and Smith-Magenis syndrome. Founded in 2008 and formerly known as Rhythm Metabolic, Inc., the company collaborates with leading clinical research organizations to advance its pipeline and address significant unmet medical needs in rare genetic obesity.
